Margaret A Horn has sold RVMD and made no open-market buys since Oct 2020

Margaret A. “Peg” Horn, J.D., is the Chief Operating Officer of Revolution Medicines, Inc. (RVMD), a clinical-stage biotechnology company developing targeted therapies for RAS-addicted cancers.( She has held this role since October 2018 and leads functions including corporate development, legal affairs, investor relations, information sciences, and facilities, helping to guide the company’s strategic growth and financing activities.( As a corporate insider, she has reported significant holdings of RVMD stock in connection with her executive role.(

Horn brings over 30 years of leadership experience in the biotechnology industry, with a career spanning senior legal, corporate development, and operational roles.( Before becoming COO at Revolution Medicines, she served there as Executive Vice President and General Counsel from 2014 to 2018, and previously was Chief Operating Officer at ProLynx LLC.( Earlier positions include Senior Vice President, Legal and Corporate Development at Kosan Biosciences, Senior Vice President, Legal at Genencor International, and legal roles at Cogentus Pharmaceuticals and E.I. du Pont de Nemours & Co., where she led major strategic transactions, collaborations, licensing deals, M&A, and multiple equity financings.( She also serves on the Board of Directors of Sangamo Therapeutics, Inc.( Horn earned a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science (now part of University of the Sciences in Philadelphia), a Juris Doctor from Villanova University Charles Widger School of Law, and an executive MBA from Pennsylvania State University.(

Written by Perplexity from public sources.